Stock analysts at Cantor Fitzgerald started coverage on shares of Dynavax Technologies Corporation (NASDAQ:DVAX) in a report released on Friday. The brokerage set an “overweight” rating and a $24.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 16.50% from the stock’s current price.

Other analysts also recently issued research reports about the stock. Cowen and Company reaffirmed an “outperform” rating and set a $30.00 price target on shares of Dynavax Technologies Corporation in a research note on Thursday, August 10th. Zacks Investment Research raised shares of Dynavax Technologies Corporation from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research note on Monday, July 10th. BidaskClub downgraded shares of Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. William Blair reaffirmed an “outperform” rating and set a $30.00 price target on shares of Dynavax Technologies Corporation in a research note on Wednesday, August 9th. Finally, J P Morgan Chase & Co raised shares of Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $6.00 to $27.00 in a research note on Monday, July 31st. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $24.67.

Dynavax Technologies Corporation (DVAX) opened at 20.60 on Friday. The firm’s 50 day moving average price is $17.04 and its 200-day moving average price is $9.40. Dynavax Technologies Corporation has a 12-month low of $3.20 and a 12-month high of $21.85. The stock’s market cap is $1.13 billion.

Dynavax Technologies Corporation (NASDAQ:DVAX) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.09. The business had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.15 million. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 92.09%. During the same quarter last year, the firm earned ($0.75) earnings per share. Equities research analysts anticipate that Dynavax Technologies Corporation will post ($1.58) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Dynavax Technologies Corporation (DVAX) Earns Overweight Rating from Analysts at Cantor Fitzgerald” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.americanbankingnews.com/2017/09/15/dynavax-technologies-corporation-dvax-earns-overweight-rating-from-analysts-at-cantor-fitzgerald.html.

Hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC purchased a new position in Dynavax Technologies Corporation during the fourth quarter valued at approximately $1,833,000. Russell Investments Group Ltd. purchased a new position in Dynavax Technologies Corporation during the fourth quarter valued at approximately $317,000. Endurant Capital Management LP increased its holdings in Dynavax Technologies Corporation by 205.4% during the first quarter. Endurant Capital Management LP now owns 173,458 shares of the biopharmaceutical company’s stock valued at $1,032,000 after buying an additional 116,658 shares during the period. Kornitzer Capital Management Inc. KS increased its holdings in Dynavax Technologies Corporation by 90.3% during the first quarter. Kornitzer Capital Management Inc. KS now owns 1,098,510 shares of the biopharmaceutical company’s stock valued at $6,536,000 after buying an additional 521,310 shares during the period. Finally, Emerald Acquisition Ltd. purchased a new position in Dynavax Technologies Corporation during the second quarter valued at approximately $472,000. 60.23% of the stock is currently owned by institutional investors.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Analyst Recommendations for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.